Will Medicare Pay for Zepbound in 2026?

Direct Answer: Does Medicare Cover Zepbound?

It depends. Original Medicare and standard Medicare Part D plans exclude Zepbound for weight loss because federal law bars Part D from covering anti-obesity drugs. Starting July 1, 2026, the temporary Medicare GLP-1 Bridge program covers Zepbound for a $50 monthly copay if you meet BMI and health-condition criteria. Standard Part D plans may still cover Zepbound when it's prescribed for moderate-to-severe obstructive sleep apnea, a separate FDA-approved use.

What Original Medicare and Standard Part D Cover

Original Medicare, meaning Part A hospital insurance and Part B medical insurance, does not pay for Zepbound in 2026 because Zepbound is a self-administered injectable drug, and Part B generally only covers drugs a doctor administers in a clinical setting. Beneficiaries who want any Zepbound coverage need either a standalone Medicare Part D prescription drug plan or a Medicare Advantage plan that bundles drug coverage.

Standard Medicare Part D plans, meaning the plans that existed before the 2026 bridge program, are legally barred from covering GLP-1 medications like Zepbound when prescribed for chronic weight management. Federal law under the Social Security Act excludes agents used for anorexia, weight loss, or weight gain from the Part D benefit, and this exclusion predates the current wave of GLP-1 weight-loss drugs by decades. Medigap policies do not change this picture: Medigap only supplements Original Medicare's Part A and Part B cost-sharing and never covers prescription drugs, so a Medigap policy cannot help pay for Zepbound under any circumstance.

The Medicare GLP-1 Bridge Program (2026 to 2027)

The Medicare GLP-1 Bridge program is a temporary CMS demonstration running from July 1, 2026 through December 31, 2027 that lets eligible Part D enrollees get Zepbound (KwikPen formulation only), Wegovy, or Foundayo for a flat $50 monthly copay. That copay does not count toward your Part D deductible or the 2026 Part D $2,100 out-of-pocket cap, and it operates outside your regular Part D plan, so your plan does not need to opt in for you to use it.

Eligibility for the bridge program depends on your body mass index (BMI) and, at lower BMI levels, an additional qualifying health condition. CMS set three tiers of qualification for 2026, summarized in the table below.

Zepbound for Sleep Apnea: The Other Path to Part D Coverage

Zepbound carries a second FDA-approved indication that sidesteps the weight-loss exclusion entirely: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, approved by the FDA in December 2024. Because this indication is not weight loss in the statutory sense, standard Medicare Part D plans and Medicare Advantage MA-PD plans are legally allowed to cover Zepbound for OSA the same way they would cover any other Part D drug, subject to their own formulary, tier placement, and prior authorization rules.

Coverage for the sleep-apnea indication is not automatic. Part D plans vary widely on which tier they place Zepbound in and whether they require a documented sleep study (polysomnography) confirming moderate-to-severe OSA plus a qualifying BMI before approving the prescription. Checking your specific plan's formulary at medicare.gov's Plan Finder, or comparing plans during the Medicare Annual Enrollment Period (October 15 to December 7, 2026, for coverage starting January 1, 2027), is the only reliable way to know your exact copay for this pathway.

What Medicare Advantage Plans Do Differently

Medicare Advantage plans that bundle drug coverage, called MA-PD plans, follow the exact same Part D statutory exclusion on weight-loss drugs as standalone Part D plans; enrolling in Medicare Advantage does not create a workaround for the weight-management indication. MA-PD enrollees can still use the 2026 GLP-1 Bridge program if they meet the BMI and condition criteria, and they can still get Zepbound covered under their plan's drug formulary if it is prescribed for sleep apnea.

Some Medicare Advantage plans have started adding supplemental, non-drug obesity-related benefits, such as nutrition counseling, weight-management coaching, or fitness-program memberships, to support members even where the drug itself is not covered. These supplemental benefits vary enormously by plan and county, so comparing Medicare Advantage plan options during the MA Open Enrollment Period (January 1 to March 31, 2026) or the Annual Enrollment Period is worth doing if a weight-management benefit matters to you.

Zepbound's Cost Without Medicare Coverage in 2026

Eli Lilly's national list price for Zepbound is $1,059.87 for a 30-day supply across all six dose strengths in 2026, and that is the price a Medicare beneficiary without any of the coverage paths above would pay out of pocket at a retail pharmacy.

LillyDirect, Eli Lilly's own pharmacy channel, offers self-pay prices well below the list price in 2026: as low as $299 to $449 a month for the lower dose strengths if you refill within 45 days, rising to $499 to $699 a month for maintenance doses without a timely refill. The separate Zepbound Savings Card, which can lower a commercially insured patient's copay to as little as $25 a month, is not available to Medicare beneficiaries, because federal law prohibits manufacturer copay-assistance cards for people enrolled in federal health programs like Medicare. LillyDirect's self-pay prices, not the savings card, are the realistic discount option for anyone on Medicare.

Alternatives if Medicare Doesn't Cover Zepbound for Weight Loss

Several paths are worth exploring before paying Zepbound's full price out of pocket.

• Try Wegovy or Foundayo through the same 2026 GLP-1 Bridge program if your pharmacy doesn't stock Zepbound's KwikPen formulation.
• Ask your Part D or MA-PD plan for a formulary exception if you have a diabetes, sleep apnea, or cardiovascular diagnosis that could support a covered indication.
• Medicare Part B still covers Intensive Behavioral Therapy for Obesity, up to 22 face-to-face counseling visits over 12 months with no cost-sharing, for beneficiaries with a BMI of 30 or higher.
• Medicare covers bariatric surgery, including gastric bypass, sleeve gastrectomy, and lap-band procedures, for beneficiaries who meet BMI and comorbidity criteria, a route with no statutory drug exclusion.
• Dual-eligible beneficiaries (Medicare and Medicaid) should check their state Medicaid program separately; a small but growing number of state Medicaid programs cover GLP-1s for obesity even though Medicare itself does not.
• Beneficiaries under 65 who lose employer coverage can compare ACA marketplace ACA-compliant plans; some state-benchmark essential health benefits packages include anti-obesity medications, though most do not yet. Losing job-based coverage no longer risks a denial for a preexisting condition, since the ACA banned preexisting condition exclusions in 2014, but that protection guarantees access to a marketplace plan, not that the plan will cover Zepbound specifically.
• Compounded tirzepatide is not a safe substitute: FDA-approved shortage-based compounding largely ended in 2025, and Medicare does not cover compounded versions of Zepbound regardless of indication.

How to Get Zepbound Covered: Next Steps

Your prescriber is the starting point for every coverage path described above. Confirming which route fits your situation before submitting any paperwork saves weeks of back-and-forth with your Part D plan.

Does Original Medicare cover Zepbound?

No. Original Medicare (Parts A and B) does not cover Zepbound in 2026 because it is a self-administered injectable drug, and Part B generally only pays for drugs a doctor administers in a clinical setting. You need a Medicare Part D plan or a Medicare Advantage plan with drug coverage to get any Zepbound benefit at all.

Does Medicare Part D cover Zepbound for weight loss?

Not under the standard Part D benefit. Federal law under the Social Security Act bars Part D from covering drugs used for weight loss. The only way to get weight-loss coverage in 2026 is through the separate Medicare GLP-1 Bridge program, which runs July 1, 2026 through December 31, 2027 for a $50 monthly copay if you meet BMI criteria.

What is the Medicare GLP-1 Bridge program?

The Medicare GLP-1 Bridge is a temporary CMS demonstration running July 1, 2026 through December 31, 2027 that lets eligible Part D enrollees get Zepbound (KwikPen only), Wegovy, or Foundayo for a flat $50 monthly copay. It operates outside your regular Part D plan and the copay does not count toward your deductible or the 2026 Part D $2,100 out-of-pocket cap.

Who qualifies for the Medicare GLP-1 Bridge program?

You must be at least 18 and meet one of three BMI tiers: a BMI of 35 or higher qualifies on its own; a BMI of 30 to 34.9 qualifies with heart failure, uncontrolled hypertension, or chronic kidney disease stage 3a or higher; a BMI of 27 to 29.9 qualifies with prediabetes, a prior heart attack or stroke, or peripheral artery disease. You're excluded if you already have Part D coverage for the drug through a diabetes, sleep apnea, or fatty liver diagnosis.

Does Medicare cover Zepbound for sleep apnea?

Yes, potentially. Zepbound was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, an indication separate from weight loss. Standard Medicare Part D and Medicare Advantage MA-PD plans can legally cover Zepbound for this use, but coverage, tier placement, and prior authorization requirements vary by plan, so check your specific formulary.

Does Medicare Advantage cover Zepbound?

Medicare Advantage plans with drug coverage (MA-PD plans) follow the same rules as standard Part D: no coverage for weight loss under the regular drug benefit, but potential coverage for sleep apnea and access to the 2026 GLP-1 Bridge program if you meet its criteria. Some MA plans add non-drug weight-management benefits like nutrition counseling as a supplemental extra.

How much does Zepbound cost without Medicare coverage in 2026?

Eli Lilly's list price is $1,059.87 for a 30-day supply across all doses in 2026. Through LillyDirect's self-pay program, prices run $299 to $449 a month for lower doses with a timely refill, rising to $499 to $699 for maintenance doses. The manufacturer's Savings Card is not available to Medicare beneficiaries.

What are the alternatives if Medicare doesn't cover Zepbound for weight loss?

Options include enrolling in the 2026 GLP-1 Bridge program, requesting a Part D formulary exception if you have a qualifying diagnosis, using Medicare Part B's covered Intensive Behavioral Therapy for Obesity counseling, pursuing Medicare-covered bariatric surgery, checking state Medicaid coverage if you're dual-eligible, or comparing ACA marketplace plans if you're under 65.